GenSpera, Inc. (GNSZ.OB) Receives US Patent for Tumor Activated Prodrugs

In the company’s news yesterday,

GenSpera, Inc. announced that the United States Patent and Trademark Office has issued the company’s patent application, entitled “Tumor Activated Prodrugs,” as US Patent 7,635,682. The patent covers the composition and potential uses of GenSpera’s G-115 second anti-cancer drug, which is currently in development.

GenSpera, Inc. owns and controls all rights to G-115. The company anticipates a strategic partnership to maximize the drug’s value as it progresses through future clinical trials. G-115 can be selectively activated within prostate tumors by an enzyme, Prostate Specific Antigen (PSA), which is active only within prostate tissue and prostate cancer tumors. In preclinical testing, G-115 was shown to dramatically inhibit the growth of tumors in animal models of human prostate cancer.

GenSpera CEO and President, Dr. Craig Dionee, Ph.D., stated, “The company commented that the issuance of this patent further strengthens GenSpera’s intellectual property position for G-115 and its uses for prostate cancer and other prostate pathologies including enlarged prostate.

Dr. Dionne continued, “We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.